GSK's Blenrep Receives China's National Medical Products Administration Approval To Treat Adults With Relapsed Or Refractory Multiple Myeloma

Benzinga Newsdesk www.benzinga.com Neutral 88.9%

Neg 0% Neu 88.9% Pos 0%

https://www.londonstockexchange.com/news-article/GSK/blenrep-approved-in-china-for-2l-multiple-myeloma/17553262

Comments

No comments yet. Be the first!